Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.71 |
| ▸ | TTK | P33981 | 5/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081503 | 0.86 | PIK3CG (0.77) | PIK3CGPIK3CDTTKPIK3CA | |
| SCHEMBL3098870 | 0.84 | PIK3CG (0.74) | PIK3CGPIK3CDTTKPIK3CAHPGD | |
| SCHEMBL3098937 | 0.83 | PIK3CG (1.00) | PIK3CGPIK3CDTTKPIK3CA | |
| SCHEMBL3090226 | 0.81 | PIK3CG (0.68) | PIK3CGPIK3CDTTKPIK3CA | |
| SCHEMBL13154308 | 0.80 | PIK3CG (0.71) | PIK3CGPIK3CDTTKPIK3CAHPGD | |
| SCHEMBL13154311 | 0.78 | PIK3CG (0.70) | PIK3CGPIK3CDTTKPIK3CA | |
| SCHEMBL1932201 | 0.72 | TTK (1.00) | TTK | |
| SCHEMBL3098985 | 0.70 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CA | |
| SCHEMBL10008771 | 0.70 | RAB9A (0.49) | HPGDSMN1; SMN2 | |
| SCHEMBL3086573 | 0.70 | PIK3CG (0.74) | PIK3CGPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | claimed |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | claimed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | claimed |
| EP-2057158-B1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LTD (GB) | 2015-08-12 | — | — | EP | disclosed |
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8883820-B2 | Triazole derivatives as kinase inhibitors | CELLZOME LTD. (GB) | 2014-11-11 | — | — | US | disclosed |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2057158-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025821-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227800-A1 | TRIAZOLE DERIVATIVES AS KINASE INHIBITORS | ITK, PIK3C3, TXK | PIK3CG 55/4885PIK3CD 19/4885TTK 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.